福森药业(01652.HK)复合磷酸氢钾注射液获批上市

阿斯达克财经
Dec 29, 2025

福森药业(01652.HK) 公布,全资附属嘉亨(珠海横琴)医药科技研发的“复合磷酸氢钾注射液”,商标为膳 维喜,上市申请已获得国家药品监督管理局批准,批准作为磷酸补充剂。该药是国家医疗保障局医保乙类品种,主要用于治疗当口服或肠内营养无法进行、不足或有禁忌时,以肠外营养补充,或患有低磷血症的成人和儿童患者。(ha/w)(港股报价延迟最少十五分钟。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10